Several biopharmaceutical companies used investor conferences in 2026 to present updates on their pipelines and commercial performance. Kura Oncology, Inc. presented at the UBS Global Biopharma Conference, as did Gilead Sciences, Inc., whose transcript was also published, while Biogen Inc. presented at the Jefferies Global Healthcare Conference.
Immunocore also addressed investors at the UBS Global Biopharma Conference 2026, where its presentation centred on KIMMTRAK, the company's product that was highlighted as a driver of growth.S4